These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

416 related articles for article (PubMed ID: 33123281)

  • 41. Aptamers: Biomedical Interest and Applications.
    Romero-López C; Berzal-Herranz A
    Pharmaceuticals (Basel); 2017 Mar; 10(1):. PubMed ID: 28300769
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Aptamer application in targeted delivery systems for diagnosis and treatment of breast cancer.
    Shahdordizadeh M; Yazdian-Robati R; Ramezani M; Abnous K; Taghdisi SM
    J Mater Chem B; 2016 Dec; 4(48):7766-7778. PubMed ID: 32263769
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Current approaches in SELEX: An update to aptamer selection technology.
    Darmostuk M; Rimpelova S; Gbelcova H; Ruml T
    Biotechnol Adv; 2015 Nov; 33(6 Pt 2):1141-61. PubMed ID: 25708387
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Nucleic acid aptamers in human viral disease.
    Zhang Z; Blank M; Schluesener HJ
    Arch Immunol Ther Exp (Warsz); 2004; 52(5):307-15. PubMed ID: 15507871
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Current Perspectives on Aptamers as Diagnostic Tools and Therapeutic Agents.
    Kumar Kulabhusan P; Hussain B; Yüce M
    Pharmaceutics; 2020 Jul; 12(7):. PubMed ID: 32659966
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Development of Cell-Specific Aptamers: Recent Advances and Insight into the Selection Procedures.
    Rahimizadeh K; AlShamaileh H; Fratini M; Chakravarthy M; Stephen M; Shigdar S; Veedu RN
    Molecules; 2017 Nov; 22(12):. PubMed ID: 29186905
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Recent advances in understanding oligonucleotide aptamers and their applications as therapeutic agents.
    Allemailem KS; Almatroudi A; Alsahli MA; Basfar GT; Alrumaihi F; Rahmani AH; Khan AA
    3 Biotech; 2020 Dec; 10(12):551. PubMed ID: 33269185
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Bioapplications of Cell-SELEX-Generated Aptamers in Cancer Diagnostics, Therapeutics, Theranostics and Biomarker Discovery: A Comprehensive Review.
    Pang X; Cui C; Wan S; Jiang Y; Zhang L; Xia L; Li L; Li X; Tan W
    Cancers (Basel); 2018 Feb; 10(2):. PubMed ID: 29425173
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Post-SELEX optimization of aptamers.
    Gao S; Zheng X; Jiao B; Wang L
    Anal Bioanal Chem; 2016 Jul; 408(17):4567-73. PubMed ID: 27173394
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Aptamers: molecular tools for analytical applications.
    Mairal T; Ozalp VC; Lozano Sánchez P; Mir M; Katakis I; O'Sullivan CK
    Anal Bioanal Chem; 2008 Feb; 390(4):989-1007. PubMed ID: 17581746
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Toward the Selection of Cell Targeting Aptamers with Extended Biological Functionalities to Facilitate Endosomal Escape of Cargoes.
    Tawiah KD; Porciani D; Burke DH
    Biomedicines; 2017 Aug; 5(3):. PubMed ID: 28837119
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Calcium Influx of Mast Cells Is Inhibited by Aptamers Targeting the First Extracellular Domain of Orai1.
    Sun R; Yang Y; Ran X; Yang T
    PLoS One; 2016; 11(7):e0158223. PubMed ID: 27390850
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A New Design for the Fixed Primer Regions in an Oligonucleotide Library for SELEX Aptamer Screening.
    Wang B
    Front Chem; 2020; 8():475. PubMed ID: 32582641
    [TBL] [Abstract][Full Text] [Related]  

  • 54. In vitro evolution of chemically-modified nucleic acid aptamers: Pros and cons, and comprehensive selection strategies.
    Lipi F; Chen S; Chakravarthy M; Rakesh S; Veedu RN
    RNA Biol; 2016 Dec; 13(12):1232-1245. PubMed ID: 27715478
    [TBL] [Abstract][Full Text] [Related]  

  • 55. RNA aptamers: from basic science towards therapy.
    Ulrich H
    Handb Exp Pharmacol; 2006; (173):305-26. PubMed ID: 16594622
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Aptamer nucleotide analog drug conjugates in the targeting therapy of cancers.
    Li Y; Zhao J; Xue Z; Tsang C; Qiao X; Dong L; Li H; Yang Y; Yu B; Gao Y
    Front Cell Dev Biol; 2022; 10():1053984. PubMed ID: 36544906
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Aptamer-iRNAs as Therapeutics for Cancer Treatment.
    Soldevilla MM; Meraviglia-Crivelli de Caso D; Menon AP; Pastor F
    Pharmaceuticals (Basel); 2018 Oct; 11(4):. PubMed ID: 30340426
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Aptamer Selection for Detecting Molecular Target Using Cell-SELEX (Systematic Evolution of Ligands by Exponential Enrichment) Technology.
    Stewart KD; Tan W; Park JY
    Methods Mol Biol; 2019; 2054():223-241. PubMed ID: 31482459
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Nucleic acid aptamer-mediated drug delivery for targeted cancer therapy.
    Zhu H; Li J; Zhang XB; Ye M; Tan W
    ChemMedChem; 2015 Jan; 10(1):39-45. PubMed ID: 25277749
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Recent Advances in Aptamer Discovery and Applications.
    Zhang Y; Lai BS; Juhas M
    Molecules; 2019 Mar; 24(5):. PubMed ID: 30866536
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.